Liquid Biopsy Detects Relapse Five Months Earlier than Regular Clinical Follow-Up and Guides Targeted Treatment in Breast Cancer

Genetic alterations in circulating tumor DNA (ctDNA) are an emerging biomarker for the early detection of relapse and have the potential to guide targeted treatment. ctDNA analysis is often performed by droplet digital PCR; however, next-generation sequencing (NGS) allows multigene testing without h...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Fiona Tsui-Fen, Lapke, Nina, Wu, Chin-Chu, Lu, Yen-Jung, Chen, Shu-Jen, Yu, Pei-Ning, Liu, Yen-Ting, Tan, Kien Thiam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754891/
https://www.ncbi.nlm.nih.gov/pubmed/31583146
http://dx.doi.org/10.1155/2019/6545298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754891/
https://www.ncbi.nlm.nih.gov/pubmed/31583146
http://dx.doi.org/10.1155/2019/6545298

Ejemplares similares